Psoriasis Patients Show Gut Microbiome Shifts Tied to Key Inflammatory Cytokines

Psoriasis has long been understood as a skin disease driven by immune misfires, but a growing body of early research points to the gut as a second theater of dysfunction. A new study published in Georgian Medical News by Algazina, Azanbayeva, Tsoy, Touir, and colleagues examined 91 patients with mild-to-moderate psoriasis alongside 92 healthy volunteers, tracking both cytokine profiles in fecal samples and the composition of gut bacterial communities. The findings are preliminary, but they add specific numbers to a concept that has been gaining traction: the gut-skin axis may be a meaningful lever in psoriasis biology.

Elevated IL-12p70 and IL-1α mark the psoriasis cytokine profile

The most striking immune signal in the data was the elevation of pro-inflammatory cytokines in psoriasis patients compared to healthy controls. IL-12p70 and IL-1α showed the most pronounced increases across the cohort. The researchers used multiplex analysis of fecal samples to measure eight cytokines in total: IL-1α, IL-4, IL-6, IL-8, IL-12p70, IL-17, IFN-γ, and TNF-α. Measuring cytokines in stool rather than serum is a less common approach, and it frames the gut compartment as its own site of inflammatory activity rather than a passive bystander.

Disease severity, measured with the Psoriasis Area and Severity Index (PASI), correlated positively with levels of IL-4, IL-8, and EGF (epidermal growth factor). In plain terms: patients with worse skin scores also showed higher concentrations of those specific immune mediators in gut samples. Whether the gut signals are driving skin inflammation, reflecting it, or both remains an open question that this study cannot answer. Prior work on gut microbiota and psoriasis immune dysregulation has similarly found links between microbial shifts and abnormal cytokine patterns, suggesting this is not an isolated observation.

Why the gut-skin axis matters for the 125 million people with psoriasis

Psoriasis affects roughly 2 to 3 percent of the global population, a group that often cycles through treatments with inconsistent results. If gut microbiome composition turns out to be a reliable correlate of disease severity, it could inform both how clinicians monitor patients and what therapies they reach for. Research on gut microbiota as a psoriasis treatment biomarker has raised the possibility that microbial profiles could predict who responds to biologics, which would be a practical tool in a field where trial-and-error prescribing is still common.

More speculatively, the microbiome itself could become a target. Microbiome-targeted therapies for psoriasis, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, are under active investigation as adjunctive treatments. None of these are standard of care yet, and the evidence base remains thin. But identifying which microbial features track with disease severity, as this study attempts, is a necessary early step before any targeted intervention can be rationally designed.

How 16S rRNA sequencing revealed gut bacterial community structure

The team used 16S rRNA gene sequencing, the standard culture-independent method for cataloguing gut bacteria, to characterize microbiome composition in both groups. Alpha-diversity, a measure of species richness and evenness within a single sample, was assessed using Shannon and Simpson indices. Beta-diversity, which captures how much microbial communities differ between individuals or groups, was assessed using Bray-Curtis dissimilarity and visualized with principal coordinates analysis.

The study also found differences in the relative abundance of specific bacterial taxa between psoriasis patients and controls, though the paper's summary does not name which genera were most affected. Multiomics approaches to psoriasis gut microbiome research have used shotgun metagenomic sequencing combined with immune profiling to go deeper than 16S rRNA alone can, identifying functional gene pathways rather than just taxonomic labels. The approach here is more modest in scope, which is appropriate for a 183-person cohort study, but it means the mechanistic picture stays incomplete.

Beta-diversity trends that PERMANOVA could not confirm

Here is where the results demand caution. Beta-diversity analysis suggested a trend toward differences in microbial community structure between psoriasis patients and healthy controls. That sounds meaningful, but the team reports that these differences were not confirmed by PERMANOVA, a statistical test designed to determine whether group-level differences in community composition are greater than what chance would produce.

A trend that fails a permutation-based significance test is not a finding; it is a hypothesis. Studies reporting altered gut microbial diversity in psoriasis have documented significant beta-diversity differences in other cohorts, so the biological signal may be real but underpowered here. With 91 patients, the study sits at the lower end of sample sizes needed to detect robust community-level differences in a condition as heterogeneous as psoriasis. Severity, treatment history, diet, geography, and antibiotic use can all shape microbiome composition independently of disease status, and none of those confounders are fully controlled in a cross-sectional design.

What comes next for gut-skin axis research in psoriasis

The authors frame the gut microbiome as both a potential biomarker and a therapeutic target, and this study provides some early scaffolding for that argument. The cytokine correlations with PASI are the most actionable piece of data here: if IL-4, IL-8, and EGF in fecal samples reliably track with skin disease activity, that connection would be worth testing in a larger, longitudinal cohort where gut and skin measurements are taken at multiple time points.

For now, treating the gut microbiome as a confirmed driver of psoriasis would be premature. What this work does is sharpen the questions: which taxa matter most, which cytokine signals are locally produced versus systemically reflected in the gut, and whether modifying the microbiome in psoriasis patients produces measurable skin improvement. Those are answerable questions, but they require study designs that go beyond what a single cross-sectional cohort can deliver.

Evidence rating

INVESTIGATIONAL — 71/100

Caveats:

• Observational design — correlations shown, not causation.
• Funding not disclosed; independent replication has not been confirmed.
• Findings are preliminary and not yet replicated in a larger independent cohort.

Observational cross-sectional study examining correlations between immune markers and gut microbiome diversity in psoriasis patients. Demonstrates association, not causation, and does not establish a step-by-step mechanistic pathway. Funding was not disclosed, and findings have not yet been independently replicated.

References

1. T Algazina, D Azanbayeva, N Tsoy, G Touir… (2026). … Parameters of the Immune Response in Psoriasis and Their Correlations with ALPHA-AND BETA-DIVERSITY of the Gut Microbiome. Georgian medical news. https://pubmed.ncbi.nlm.nih.gov/42289130/
2. Xinyue Zhang, Linjing Shi, Ting Sun, Kun Guo, Songmei Geng (2021). Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients. BMC Microbiology. https://doi.org/10.1186/s12866-021-02125-1
3. Karina Polak, Beata Bergler-Czop, Michał Szczepanek, Kamila Wojciechowska, Aleksandra Frątczak, Norbert Kiss (2021). Psoriasis and Gut Microbiome—Current State of Art. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22094529
4. Xinyan Zou, Xinfu Zou, Longxia Gao, Hanqing Zhao (2024). Gut microbiota and psoriasis: pathogenesis, targeted therapy, and future directions. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1430586
5. Hsin-Wen Chang, Di Yan, Rasnik Singh, et al. (2022). Multiomic Analysis of the Gut Microbiome in Psoriasis Reveals Distinct Host‒Microbe Associations. JID Innovations. https://doi.org/10.1016/j.xjidi.2022.100115
6. Jianfei Chen, Keyun Sun, Xinyu Zhang, et al. (2025). Psoriasis and gut microbes: research advances from mechanism to therapy. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2025.1711288